GlassScriptPhysician profile
Muna Basnet Bhattarai
NPI 1306304845
$13,289.03
in general payments reported to CMS, 2019-2025
65 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $1,585 · 2023: $3,680 · 2024: $4,725 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,759.16 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,988.84 | 2021-2025 | |
| Biogen, INC. | $729.90 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $718.14 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $533.31 | 2023-2025 | |
| Lilly USA, LLC | $483.50 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $401.12 | 2021-2025 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $398.42 | 2022-2024 | Ultomiris, Soliris |
| Emd Serono, INC. | $383.75 | 2021-2025 | Mavenclad |
| Pfizer INC. | $366.85 | 2023-2025 | |
| Sk Life Science, INC. | $335.75 | 2022-2025 | |
| Grifols USA, LLC | $335.00 | 2023-2025 | Gamunex-C |
| Neurocrine Biosciences, INC. | $318.09 | 2021-2024 | Ingrezza, Ongentys |
| Alnylam Pharmaceuticals INC. | $313.32 | 2022-2025 | Onpattro, Amvuttra |
| Argenx US, INC. | $295.79 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $292.03 | 2024-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $277.08 | 2022-2025 | Crexont, Rytary, Ongentys |
| Merz Pharmaceuticals, LLC | $260.47 | 2023-2024 | Xeomin |
| Acadia Pharmaceuticals INC | $231.62 | 2023-2025 | Nuplazid, Daybue |
| Tanabe Pharma America, INC. | $213.60 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $206.33 | 2022-2024 | Gammagard, Hyqvia |
| Biohaven Pharmaceuticals, INC. | $205.81 | 2021 | |
| Genentech USA, INC. | $198.30 | 2022-2024 | Ocrevus |
| Lundbeck LLC | $184.90 | 2024 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $183.12 | 2022 | |
| Amgen INC. | $171.07 | 2021-2025 | Uplizna |
| Csl Behring | $169.02 | 2021-2024 | Hizentra |
| Amylyx Pharmaceuticals, INC. | $151.38 | 2023-2024 | Relyvrio |
| Ani Pharmaceuticals, INC. | $139.69 | 2022-2025 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $120.93 | 2021-2023 | |
| Octapharma USA, INC. | $120.62 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Tg Therapeutics, INC. | $112.49 | 2023-2025 | |
| Avion Pharmaceuticals | $97.60 | 2022-2023 | Dhivy |
| Sumitomo Pharma America, INC. | $94.25 | 2023 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $84.19 | 2023-2024 | Nuedexta, Rexulti |
| Jazz Pharmaceuticals INC. | $76.32 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $70.81 | 2022-2023 | Ponvory |
| Upsher-Smith Laboratories LLC | $68.94 | 2021-2022 | |
| Axsome Therapeutics, INC. | $67.75 | 2023-2025 | Sunosi, Symbravo |
| Aucta Pharmaceuticals, INC. | $63.06 | 2024 | Motpoly Xr |
| Vanda Pharmaceuticals INC. | $56.94 | 2024-2025 | Ponvory |
| Ge Healthcare | $53.00 | 2022-2024 | |
| Sandoz INC. | $46.76 | 2023-2024 | |
| Banner Life Sciences, LLC | $44.70 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $44.49 | 2024 | |
| Nevro Corp. | $40.42 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $40.35 | 2023-2024 | Dysport |
| Genzyme Corporation | $40.21 | 2022-2024 | |
| Ns Pharma, INC. | $37.27 | 2025 | Viltepso |
| Acorda Therapeutics, INC | $35.56 | 2023 | Inbrija |
| Harmony Biosciences LLC | $33.64 | 2022-2024 | |
| Janssen Biotech, INC. | $33.46 | 2025 | |
| Celgene Corporation | $32.84 | 2023-2025 | Zeposia |
| Medtronic, INC. | $31.85 | 2023-2024 | Intellis Adaptivestim |
| Grt US Holding, INC. | $30.17 | 2022 | |
| Cala Health, INC. | $29.94 | 2025 | Cala Kiq |
| Ultragenyx Pharmaceutical INC. | $28.23 | 2025 | Dojolvi |
| Astrazeneca Pharmaceuticals LP | $24.10 | 2025 | Wainua |
| Sanofi-Aventis U.S. LLC | $23.02 | 2021 | |
| Boston Scientific Corporation | $22.15 | 2024 | |
| 3b Medical, INC. | $19.51 | 2025 | Luna |
| Avadel Cns Pharmaceuticals, LLC | $17.91 | 2025 | Lumryz |
| Catalyst Pharmaceuticals, INC. | $16.84 | 2023 | Firdapse |
| Azurity Pharmaceuticals, INC. | $15.41 | 2025 | |
| Horizon Therapeutics Plc | $15.09 | 2023 | Uplizna |
| Arbor Pharmaceuticals, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muna Bhattarai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.